PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Vismodegib in basal cell carcinoma: Added benefit not proven

Hardly any patient-relevant outcomes were investigated/ studies without control groups

2013-11-18
(Press-News.org) Contact information: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Vismodegib in basal cell carcinoma: Added benefit not proven Hardly any patient-relevant outcomes were investigated/ studies without control groups The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma (BCC): symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. However, no added benefit can be derived from the data presented in the company's dossier.

Currently hardly any chances of cure in advanced basal cell carcinoma

Basal cell carcinoma (also called "basalioma") is a malignant form of skin cancer, which mainly occurs on the head or neck. In most cases, timely surgery can prevent it from spreading. In an aggressive ("locally advanced") form and the occurrence of metastases, however, treatment options are limited. Often only symptoms can be relieved, but cure is no longer possible.

The manufacturer has now presented data from an approval study. According to this study, tumours shrank under vismodegib in some patients with symptomatic metastatic or locally advanced BCC.

G-BA distinguished different comparator therapies

The Federal Joint Committee (G-BA) specified several appropriate comparator therapies: In patients with symptomatic metastatic BCC for whom surgery was not an option, the drug was to be compared with radiotherapy. In patients with symptomatic metastatic BCC for whom radiotherapy was inappropriate, surgery was to be used as comparator therapy. In patients with symptomatic metastatic or locally advanced BCC for whom neither radiotherapy nor surgery was an option, the benefit of vismodegib was to be compared with the benefit of best supportive care. "Best supportive care" means palliative treatment tailored to the individual patient, i.e. a treatment that does not aim to cure, but to alleviate symptoms as good as possible (e.g. with adequate pain therapy) and improve quality of life.

Pharmaceutical company deviated from the G-BA's specification

In contrast to the G-BA's specifications, the pharmaceutical company exclusively compared its drug with best supportive care – claiming that surgery and radiotherapy in symptomatic metastatic BCC also had only a palliative effect. IQWiG did not accept this deviation from the specified appropriate comparator therapy: If it is assumed that different treatments are optimal for different patient groups, this differentiation also has to have an effect on the control groups.

Studies unsuitable for assessing the added benefit

However, the main problem was that the dossier was based solely on studies without control groups. An added benefit can only be derived from this kind of studies if "dramatic" patient-relevant effects occur in these studies. To estimate the effect size, other studies would have to be used for comparison – in this case, studies known as "historical controls". If, for example, most patients died early in the historical controls, but many patients survived longer in the study with the new drug, this would be a "dramatic effect".

Based on the study data submitted, it was not possible to assess whether there were dramatic effects with regards to patient-relevant outcomes because tumour regression mainly measured with imaging techniques (the so-called "objective response rate") is a surrogate outcome and not necessarily patient-relevant. Moreover, the pharmaceutical company did not present any data on the appropriate comparator therapy so that no comparison could be made. Hence an added benefit versus the appropriate comparator therapy is not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on vismodegib.

### The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of vismodegib.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.


ELSE PRESS RELEASES FROM THIS DATE:

Amber provides new insights into the evolution of the Earth's atmosphere

2013-11-18
Amber provides new insights into the evolution of the Earth's atmosphere Scientists encounter big challenges when reconstructing atmospheric compositions in the Earth's geological past because of the lack of useable sample material. One of the few ...

Would an 'anti-ketamine' also treat depression?

2013-11-18
Would an 'anti-ketamine' also treat depression? Yes, says a new study in Biological Psychiatry Philadelphia, PA, November 18, 2013 – Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing ...

More than 600 ancient seals and amulets found

2013-11-18
More than 600 ancient seals and amulets found Archaeologists from the Cluster of Excellence make an unusually large find in Turkey -- surprisingly vivid insights into the piety of the time Classical scholars from the Cluster of Excellence "Religion ...

Nature: Single-atom bit forms smallest memory in the world

2013-11-18
Nature: Single-atom bit forms smallest memory in the world This news release is available in German. One atom equals one bit: According to this design principle, we would like to construct magnetic data memories in the future. Presently, a compound of several ...

First EU e-Inclusion map measures the potential for improved digital literacy

2013-11-18
First EU e-Inclusion map measures the potential for improved digital literacy An EU-27 survey of intermediary organisations operating on the education, social and employment sectors and providing IT training has produced a first ever assessment ...

Cesarean delivery doesn't lower risk of cerebral palsy

2013-11-18
Cesarean delivery doesn't lower risk of cerebral palsy Cesarean deliveries do not prevent children from developing cerebral palsy, despite long-held medical and community beliefs about the causes of cerebral palsy, according to new research ...

A study led by CNIO validates a new anti-cancer therapy based on cell division

2013-11-18
A study led by CNIO validates a new anti-cancer therapy based on cell division The study confirms the therapeutic potential of inhibiting Aurora-A in cancer treatment Aurora-A is a protein involved in the cell division process that is highly expressed ...

Spanish scientists are designing a robot for inspecting tunnels

2013-11-18
Spanish scientists are designing a robot for inspecting tunnels Currently, maintenance and safety inspection of tunnels used for vehicular traffic is carried out by direct in situ observation. This process, which is slow and requires intensive labor, requires that traffic ...

Boredom research has now become more interesting

2013-11-18
Boredom research has now become more interesting Researchers identify fifth type of tedium -- apathetic boredom Being bored has just become a little more nuanced, with the addition of a fifth type of boredom by which to describe this emotion. The finding has been published ...

Teens who drink alone more likely to develop alcohol problems as young adults

2013-11-18
Teens who drink alone more likely to develop alcohol problems as young adults Results also show adolescents drink alone to cope with negative emotions PITTSBURGH—Most teenagers who drink alcohol do so with their friends in social settings, but a new study by researchers ...

LAST 30 PRESS RELEASES:

Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training

Day-long conference addresses difficult to diagnose lung disease

First-ever cardiogenic shock academy features simulation lab

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

[Press-News.org] Vismodegib in basal cell carcinoma: Added benefit not proven
Hardly any patient-relevant outcomes were investigated/ studies without control groups